Content

Tirzepatide for Sleep Apnea: What Was Approved

Creator: Julian Reyes, Health Writer
Published: 2026-08-25

In December 2024 Zepbound became the first medicine approved in the United States for moderate-to-severe obstructive sleep apnea in adults with obesity. The trials behind it are specific, and so is what that approval does and does not cover.

Julian Reyes, Health Writer August 25, 2026 6 min read

A man in a long-sleeve henley sits on the edge of a made bed in soft morning light

The short version

On December 20, 2024 the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for moderate to severe obstructive sleep apnea in adults with obesity — the first medicine ever approved for the condition — alongside a reduced-calorie diet and increased physical activity.
In SURMOUNT-OSA, the apnea-hypopnea index fell 25.3 events per hour on tirzepatide versus 5.3 on placebo in adults not using PAP, and 29.3 versus 5.5 in adults who stayed on PAP, over 52 weeks.
At week 52, 42.2% (not using PAP) and 50.2% (on PAP) of tirzepatide participants reached an AHI under 5, or 5 to 14 with no significant daytime sleepiness, against 15.9% and 14.3% on placebo.
It is an adjunct, not a substitute: trial 2 participants stayed on PAP throughout, and the American Academy of Sleep Medicine says the goal is not to replace CPAP.
The dosage named for the sleep-apnea indication is 10 mg or 15 mg once weekly, narrower than the weight indication, which also allows 5 mg.
Tirzepatide through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: it is not FDA-approved, for sleep apnea or for any other indication.

Tirzepatide for sleep apnea means one specific thing. On December 20, 2024 the U.S. Food and Drug Administration approved Zepbound — the brand-name tirzepatide injection — to treat moderate to severe obstructive sleep apnea in adults with obesity, in combination with a reduced-calorie diet and increased physical activity. It was the first medicine ever approved for that condition. The evidence was SURMOUNT-OSA, two 52-week trials in which tirzepatide cut the apnea-hypopnea index by 25 to 29 events an hour. It is not a replacement for CPAP, and the approval does not extend to compounded tirzepatide, which carries no approved indication of any kind.

What tirzepatide for sleep apnea was approved to treat

The prescribing information is narrow, and it is worth reading literally. Zepbound is indicated "to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity" and, like its weight indication, only "in combination with a reduced-calorie diet and increased physical activity". Two things have to be true at once: an apnea-hypopnea index of at least 15 events per hour, the clinical threshold for moderate OSA, and obesity.

The dosing is narrower too. Where the weight indication allows 5 mg, 10 mg or 15 mg once weekly, the sleep-apnea indication names only 10 mg or 15 mg. Treatment still begins at 2.5 mg weekly for four weeks, which the labeling describes as an initiation step rather than a maintenance dose, and the prescriber sets the schedule from there.

The agency's announcement called it "the first drug treatment option for certain patients with obstructive sleep apnea". The word "certain" is doing real work. Sleep apnea that is not driven by excess weight is not what this was studied in.

What SURMOUNT-OSA measured

SURMOUNT-OSA was two parallel phase 3 trials, both 52 weeks, both randomized against placebo, published in the New England Journal of Medicine in 2024. Trial 1 enrolled 234 adults who were unable or unwilling to use positive airway pressure. Trial 2 enrolled 235 adults who were on PAP and stayed on it. Participants took the maximum tolerated dose, 10 mg or 15 mg once weekly. Mean baseline AHI was 51.5 events per hour in trial 1 and 49.5 in trial 2 — severe, in both.

The primary endpoint was the change in AHI at week 52.

Trial	Tirzepatide	Placebo	Treatment difference
Trial 1 (not using PAP)	−25.3 events/hour	−5.3	−20.0
Trial 2 (staying on PAP)	−29.3 events/hour	−5.5	−23.8

Both differences were significant at P<0.001. Body weight fell 17.7% in trial 1 and 19.6% in trial 2, against 1.6% and 2.3% on placebo. At week 52, 42.2% of trial 1 participants and 50.2% of trial 2 participants on tirzepatide had an AHI below 5, or 5 to 14 with no significant daytime sleepiness — against 15.9% and 14.3% on placebo.

Symptoms moved as well, which matters more to most people than an index does. A separate analysis of the patient-reported outcomes in Sleep Medicine in 2025 found improvements in sleep-related impairment, sleep disturbance, daytime functioning and quality of life. Post-hoc analyses published in Sleep in 2026 found the people who felt worst at baseline — the most fatigued, the sleepiest, the poorest sleepers — reported the largest symptom improvements, while the measured AHI improvement was similar across those subgroups.

Adverse events were mostly gastrointestinal and mostly mild to moderate. Diarrhea was reported by 26.3% of tirzepatide participants in trial 1 and 21.8% in trial 2, nausea by 25.4% and 21.8%. Tirzepatide side effects covers the full profile.

It does not replace CPAP for everyone

This is the most misread part of the story. Trial 2 participants stayed on positive airway pressure throughout the study, with PAP withdrawn only for the sleep-study assessments so the drug's own effect could be read. The trials tested tirzepatide alongside PAP, not instead of it.

The American Academy of Sleep Medicine says so directly in its guidance for clinicians: "The goal of tirzepatide therapy is not to replace traditional OSA treatments like CPAP, but to provide an adjunctive tool that targets the root cause in many patients: excess weight." The same guidance adds that CPAP should not be discontinued without proper reassessment, and that stopping tirzepatide may undo the AHI reduction gained while on it.

Two practical consequences follow. Sleep apnea is graded by a sleep study, so a change in severity is something to be measured rather than inferred from feeling better. And a device already prescribed to you is not something to abandon on your own initiative.

Who the trials enrolled, and who they left out

Entry required moderate-to-severe OSA, defined as an AHI of at least 15 events per hour, plus obesity — a body-mass index of at least 30, or at least 27 in Japan. Mean BMI was 39.1 in trial 1 and 38.7 in trial 2. Excluded were people with type 1 or type 2 diabetes, central or mixed sleep apnea, major craniofacial abnormalities, planned sleep-apnea or obesity surgery, and anyone whose weight had moved more than 5 kg in the three months before screening.

That exclusion list is the honest boundary of the evidence. SURMOUNT-OSA says nothing about sleep apnea at a normal weight, nothing about central sleep apnea, and nothing about airway anatomy as the dominant cause.

Where compounded tirzepatide sits

Here is the line, drawn precisely. The approval attaches to the brand product for that indication — not to the molecule, and not to every preparation containing it. Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved, for obstructive sleep apnea or for anything else. Compounded medications are not reviewed for safety, effectiveness or quality the way an approved product is.

So nothing on this site is offered as a treatment for sleep apnea, and any seller implying otherwise is claiming something the approval does not cover. What Promise's prescriber network reviews is a request for compounded tirzepatide, judged on the clinical picture you present. Regulatory status is one input into a prescribing decision rather than the whole of it, and a licensed provider may still prescribe a compounded formulation where they judge it appropriate — that decision is between you and your doctor. Tirzepatide brand names sets out which branded products carry which indications, because they are not interchangeable.

What to raise with a prescriber

If sleep apnea is part of your history, say so at intake, whether or not it is the reason you are asking. A provider will want to know if you have a diagnosis and a sleep study, whether you use PAP and how well you tolerate it, and what else you are being treated for. Type 2 diabetes, a personal or family history of medullary thyroid carcinoma, pancreatitis, gallbladder disease and pregnancy all change the answer, and some of them close it.

At Promise, a licensed provider reviews every request and prescribes only when tirzepatide is appropriate for you. Not everyone qualifies. Tirzepatide clinical trials gathers what the SURMOUNT program has measured across indications, if you want the wider evidence picture first.

Common questions

Is tirzepatide approved for sleep apnea?

Yes, but only the brand product. On December 20, 2024 the U.S. Food and Drug Administration approved Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea in adults with obesity, used with a reduced-calorie diet and increased physical activity. It was the first drug treatment option for the condition. The indication requires both an apnea-hypopnea index of at least 15 events per hour and obesity.

Is compounded tirzepatide approved for sleep apnea?

No. FDA-approved tirzepatide is sold under the brand name Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, and the compounded formulation offered here is not FDA-approved for that indication or any other. A licensed provider may still prescribe a compounded formulation where they judge it appropriate — that decision is between you and your doctor.

How much did tirzepatide reduce sleep apnea in the trials?

In SURMOUNT-OSA, the apnea-hypopnea index fell by 25.3 events per hour over 52 weeks in adults not using PAP, against 5.3 on placebo, a treatment difference of 20.0 events per hour. In adults who stayed on PAP it fell 29.3 versus 5.5, a difference of 23.8. Mean baseline AHI was around 50 events per hour in both trials.

Can tirzepatide replace CPAP?

Not on the current evidence. In SURMOUNT-OSA trial 2, participants stayed on positive airway pressure throughout, and the American Academy of Sleep Medicine states that the goal of tirzepatide therapy is not to replace treatments like CPAP but to add a tool targeting excess weight. It also says CPAP should not be discontinued without proper reassessment, which means a repeat sleep study rather than a judgment call.

What dose of tirzepatide is used for obstructive sleep apnea?

The labeled maintenance dosage for the sleep-apnea indication is 10 mg or 15 mg injected subcutaneously once weekly, narrower than the weight indication, which also allows 5 mg. Treatment still begins at 2.5 mg once weekly for four weeks, which the labeling describes as an initiation step rather than a maintenance dosage. The prescriber sets the actual schedule.

Does tirzepatide help sleep apnea in people who are not overweight?

The trials do not answer that question. SURMOUNT-OSA enrolled only adults with obesity, a body-mass index of at least 30 or at least 27 in Japan, and mean BMI was near 39. People with central or mixed sleep apnea, major craniofacial abnormalities, and type 1 or type 2 diabetes were excluded. The indication is written for adults with obesity for that reason.

What side effects were reported in the sleep apnea trials?

Mostly gastrointestinal, and mostly mild to moderate. In SURMOUNT-OSA, diarrhea was reported by 26.3% of tirzepatide participants in trial 1 and 21.8% in trial 2, and nausea by 25.4% and 21.8%, with vomiting and constipation less common. Adverse events led 4.4% and 3.4% of tirzepatide participants to stop the trial drug.